Innova Nanojet Technologies
AirSancta® is a healthcare-focused air purification brand developed by Innova NanoJet Technologies Ltd, a UK-based innovator in infection prevention solutions. Powered by proprietary NanoJet® Technology, AirSancta systems use water-based nano-aerosolisation to rapidly capture and neutralise airborne pathogens, allergens, odours and pollutants—without filters or chemicals. Designed for use across healthcare and care environments, AirSancta products provide fast, effective room decontamination and ongoing air quality management, supporting safer indoor spaces for patients, staff and visitors.
Our approach to healthcare is centred on prevention, protection and practicality. We believe effective infection prevention should be proactive, evidence-led and easy to integrate into real-world clinical workflows. By focusing on airborne transmission—an often under-addressed infection risk—we support healthcare providers in strengthening environmental hygiene without increasing chemical exposure or operational burden. We work closely with clinicians, infection prevention specialists and independent laboratories to ensure our solutions are credible, measurable and aligned with evolving healthcare standards.
AirSancta® systems address the critical challenge of airborne infection risk in healthcare settings. Our technology rapidly reduces airborne pathogens, allergens and odours, helping to improve indoor air quality in patient rooms, wards, clinics and care facilities. By operating without filters or chemicals, our solutions reduce consumable waste, simplify maintenance and minimise disruption to clinical environments. This supports safer spaces for vulnerable patients, protects healthcare staff, and complements existing infection prevention and cleaning protocols.
Our core innovation is NanoJet® Technology—a proprietary, filter-free approach to air purification that uses water to generate nanoscale droplets capable of capturing airborne contaminants. Unlike conventional filtration systems, NanoJet® delivers rapid air treatment in short operational cycles and can be deployed flexibly across multiple rooms. Ongoing innovation includes independent laboratory validation, sector-specific product development, and expanding applications across healthcare, care homes and high-risk indoor environments.
Our future direction focuses on expanding the role of air as a controllable element of infection prevention. We are continuing independent testing, strengthening clinical and institutional partnerships, and broadening deployment of AirSancta® systems across healthcare and care settings in the UK and internationally. Upcoming initiatives include further product development, additional healthcare validations, and deeper collaboration with infection prevention professionals to support safer indoor environments and improved patient outcomes.